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Effects of ischaemia and reoxygenation on cardiac contractile function can be abrogated 
by ischaemic preconditioning (IPC). We tested whether β-adrenoceptor agonists could 
mimic IPC and whether IPC was dependent on β-adrenoceptor activation in rat isolated 
cardiac tissues. 
Paced left atria and right ventricular strips were set-up in Krebs’ solution and isometric 
developed tension recorded. Ischaemia was simulated by replacing with hypoxic glucose-
free Krebs’ solution for 30 minutes. IPC and isoprenaline (10-7M) preconditioning for 10 
minutes were examined. Developed tension post-reoxygenation was expressed as a 
percentage of the pre-ischaemic baseline. 
Recovery at 15 minutes was significantly increased by IPC in atria (47±4.0 % v. 29.3±1.7 
%, p<0.05) and ventricles (39.0±5.2 % v. 22.4±2.8%, p<0.05). At 60 minutes, 
isoprenaline treated atria recovery (75.8±16.6%) was significantly (p<0.05) greater than 
controls (47.9±2.3%). Propranolol (10-6M) abolished both effects. 
Therefore, both IPC and β-adrenoceptor agonist-induced improvement of contractile
recovery was propranolol-sensitive and β-adrenoceptor mediated. 
Keywords:  β-adrenoceptor; Cardioprotection; Heart; Ischaemia/reperfusion; 
Preconditioning; Rat.
Abbreviations: β-adrenoceptor-mediated preconditioning, βP; Ischaemic 
Preconditioning, IPC;  Propranolol, Pro;  Protein kinase A, PkA 
































































Ischaemic preconditioning is an extremely powerful cardioprotective phenomenon 
whereby transient periods of ischaemia protect the heart against later more severe 
ischaemic insult. The phenomenon, first discovered by Reimer’s group (Murry et al.
1986) protects the heart against arrhythmias (Ravingerová et al. 2002) and importantly 
prevents lethal cell injury and reduces infarct size (Jennings 1996). However, controversy 
exists as to whether preconditioning reduces stunning (contractile dysfunction of a 
reversible nature) (Jennings 1996).  Whilst the salutatory effects of preconditioning are 
undoubted, induction of ischaemia is impractical for widespread use in the clinic, thus 
attempts have been made to understand the mechanisms behind this protective 
phenomenon in order that it can be replicated pharmacologically.
Several groups (Frances et al. 2003; Lange et al. 2006a; Lochner et al. 1999; Marais et al.
2001; Moolman et al. 2006a; Moolman et al. 2006b; Nasa et al. 1997; Robinet et al.
2005; Tong et al. 2005; Yabe et al. 1998). including ourselves (Yates et al. 2003) have 
demonstrated that a preconditioning-like adapted state can be induced by transient pre-
treatment with an agonist of the β-adrenoceptor However it is unclear whether or not 
ischaemic preconditioning is dependent on β-adrenoceptor activation (Frances et al. 2003; 
Iliodromitis et al. 2004; Spear et al. 2007; Tong et al. 2005) .  
 Much of this work has been carried out using the Langendorff perfused heart, an 
excellent model for studying ischaemic damage and reperfusion injury, as both functional 
data and infarct-size data can be obtained. However, results obtained from isolated hearts 
and indeed in vivo procedures are complicated by the fact that activation of β2-
adrenoceptors in the coronary vasculature, leads to coronary vasodilatation (Tune et al.
2004). Activation of β-adrenoceptors in the heart also results in a positive chronotropic 































































response (Ahlquist, 1948) which may be another confounding factor unless rate is held 
constant by electrically pacing the preparations.
We therefore utilised electrically paced isolated cardiac tissues which allowed us to study 
the direct effects of ischaemic preconditioning and drug treatment on contractile function 
in different regions of the heart. As this model does not involve coronary flow, then true 
ischaemia cannot be induced, however ischaemia was simulated by using a hypoxic 
buffer containing no glucose. Reperfusion was simulated by replacing normal buffer and 
reoxygenating the tissues. 
It was therefore our aim to test the hypothesis that ischaemic preconditioning and β-
adrenoceptor-mediated preconditioning could be demonstrated in isolated paced cardiac 
tissues which provide a coronary-vascular-independent model of myocardial ischaemia. 
One would expect β-adrenoceptor-mediated preconditioning to be susceptible to a β-
adrenoceptor antagonist, however we also aimed to test the hypothesis that ischaemic 
preconditioning is dependent on β-adrenoceptor activation by endogenously released 
catecholamines in this model.
Methods
Atrial preparations
Male Sprague-Dawley rats (Harlan, Bicester, U.K.) were used throughout and weighed 
250-350g at the time of killing. These studies complied with the guidelines for the care 
and use of laboratory animals according to the Animals (Scientific Procedures) Act 1986. 
Rats were killed by a blow to the head followed by cervical dislocation. The abdominal 
cavity was opened using curved scissors and lateral incisions were made on each side of 































































the rib cage to expose the heart. The pericardium was removed and the heart was clamped 
at the apex using a pair of Spencer-Wells forceps. The left atrial appendage was lifted 
using curved forceps and a 5-0 suture was inserted through the tip and tied off for 
attachment to an isometric transducer (Pioden dynamometer UF1 range ± 55g). Another 
suture was inserted at the atrioventricular junction for securing the tissue to a bipolar 
platinum electrode. The atrial appendage was then cut free from the ventricle and 
immediately immersed in ice-cold Krebs’ solution (composition (in mM): NaCl 118.4; 
MgSO4 1.2; KCl 4.7; CaCl2.6H2O 2.5; KH2PO4 1.2; NaHCO3 25.0 and glucose 11.7)  
gassed with 95% O2  in CO2 . A suture was then inserted into the apical end of the right 
ventricular muscle and tied off for attachment to an isometric transducer. A strip
approximately 4 mm wide and 20 mm long was then cut by dissecting up to the 
atrioventricular border where another suture was passed through the tissue for attaching
the tissue to an electrode. Both tissues were submerged in ice-cold Krebs’ whilst they 
were being tied on to the electrodes before being transferred to a 20 ml organ bath
containing Krebs solution at 37˚C gassed with 5% CO2 in O2. Contractile tension was 
measured via transducers, the signal was amplified using a Grass model 79D EEG 
polygraph data recording system (Grass instrument Co. Quincy, Mass., U.S.A.), 
converted from analogue to digital data using a Powerlab 200 (ADInstruments), and 
passed to a computer. Data were recorded at a sampling frequency 200 Hz using Chart 
v.4.1.1 software (ADInstruments). The apparatus was adjusted so that there was an initial 
resting tension of 1±0.1g on atrial preparations and 1.5±0.1g on ventricles. Both tissues 
received punctuate electrical stimulation via a bipolar platinum electrode at 2Hz and
150% of the threshold voltage required to cause contraction. All preparations were left 
for one hour to stabilise, during which time they were frequently washed.
After the stabilisation period, the tissues were randomised to one of the following 
treatment groups (Fig. 1). Control; tissues underwent a further thirty minutes normoxia, 
followed by  30 minutes simulated ischaemia, achieved by bathing the tissues in glucose-
free Krebs’ and gassing with 5% CO2 in N2. Glucose-free Krebs’ contained choline 































































chloride 7mM in order to maintain osmolarity (Carr et al. 1997). Normoxic glucose-
containing Krebs’ was then restored and the contractile function of the tissues was 
monitored for one hour, during which time the Krebs’ was replaced every fifteen minutes. 
Ischaemic preconditioning (IPC); tissues underwent ten minutes of simulated ischaemia 
and ten minutes normal oxygenation prior to the index ischaemia. Ischaemic 
preconditioning in the presence of propranolol (IPC + Pro). Ischaemic preconditioning 
was performed as described as above, in the presence of 10-6 M propranolol which was 
added twenty-five minutes prior to the preconditioning ischaemia and maintained 
throughout simulated ischaemia and throughout the experiment after reoxygenation and 
glucose replacement. β-adrenoceptor-mediated preconditioning (βP). Tissues were 
exposed to isoprenaline (10-6 M) under normoxic conditions for 10 minutes, followed by 
washout. Simulated ischaemia began twenty minutes later. β-adrenoceptor-mediated 
preconditioning in the presence of propranolol (βP + Pro). Tissues were exposed to 
propranolol (10-6 M) for fifteen minutes prior to isoprenaline treatment as described 
above. Propranolol was maintained throughout the experiment. The protocols for 
ischaemic and pharmacological preconditioning were chosen based on preliminary data 
to find the optimum protocols for protection in this model.
The tissues were washed by replacing the Krebs’ solution with fresh warmed oxygenated 
Krebs’ three times. Tissues were paced throughout the experiment using a Grass S48 
stimulator (Grass instrument Co. Quincy, Mass., U.S.A.) with threshold voltage + 50% 
(typically 1-5 V) at 2 Hz .
Materials
All Krebs’ components and ascorbic acid were purchased from Fisher Scientific 
(Loughborough, UK). (−)-Isoprenaline (+)-bitartrate and (±)-propranolol were obtained 
from Sigma Aldrich (Poole, UK). Drugs were prepared daily as fresh solutions in distilled 
water.  
































































Prism version 4.02 for windows (GraphPad Software, Inc) was used for production of 
graphs and statistical analyses. Tension was monitored continuously, enabling calculation 
of diastolic (baseline) and developed tension. The degree of ischaemic contracture was 
quantified by measuring the increase in diastolic tension during simulated ischaemia at its 
maximum point (Fig. 2). The time taken to reach maximal contracture was also recorded. 
Cardiac function was assessed at fifteen and sixty minutes post reoxygenation. Developed 
tension at these time points was calculated as a percentage of developed tension at the 
end of the stabilization period for each preparation. Groups of data were compared by 
one-way ANOVA followed by Tukey’s post hoc test.
Results
Effect of simulated ischaemia on contractile function
In control preparations in both atria and ventricles, simulated ischaemia led to a rapid 
reduction in developed tension, which fell to near-zero levels after five minutes. Diastolic 
tension rose during simulated ischaemia reaching a maximum between 20 and 25 minutes 
and fell thereafter. Maximum contracture was 0.65 ± 0.1g in atria and 1.94 ± 0.18 g in 
ventricles. Upon reoxygenation, recovery of developed tension occurred rapidly during 
the first 15 minutes, and more slowly thereafter (Fig. 2). Therefore we chose to compare 
contractile function at 15 and 60 minutes post-reoxygenation.































































Effects of ischaemic and β-adrenoceptor-mediated preconditioning on  
ischaemic contracture
Ischaemic preconditioning in ventricular tissues led to a significant (p<0.05) reduction in 
maximal ischaemic contracture from 1.95 ± 0.18g in controls to 0.92 ± 0.28g. A similar
trend was evident in atrial tissues although this did not reach significance. β-
Adrenoceptor-mediated preconditioning did not alter the maximal contracture compared 
with controls (Fig. 3).
Ischaemic preconditioning led to a significant (p<0.01) reduction in the time taken to 
achieve maximal contracture in ventricular tissue from 22.5 ± 3.5 minutes in controls to 
16. 3 ± 1.5 minutes. β-Adrenoceptor-mediated preconditioning did not alter the time 
taken to reach maximal contracture (Fig. 4).
Propranolol alone had no significant effect on either the magnitude of the maximal 
contracture, or the time taken to achieve this contracture. When ischaemic 
preconditioning was carried out in the presence of propranolol, the magnitude of 
ischaemic contracture was neither significantly different from control nor preconditioned 
ventricular tissues. In atria, however, the combination of ischaemic preconditioning and 
propranolol led to an ischaemic contracture of 1.58 ± 0.36g which was significantly 
(p<0.001) greater than either control atria or those which had undergone ischaemic 
preconditioning.
Effects of ischaemic preconditioning on contractile recovery
The timecourse of developed tension in atria and ventricles is shown in Figure 5.































































Ischaemic preconditioning led to an improved recovery of developed tension in both 
atrial and ventricular preparations compared with controls (Fig. 5). The improvement in 
recovery was significant at fifteen minutes after reoxygenation (Fig. 6). By this time 
point, developed tension in control (untreated) atrial tissues had recovered to 29.3 ± 1.7 
% of the preischaemic developed tension. Recovery of function was significantly 
(p<0.05) improved to 47.0 ± 4.0 % in tissues that had undergone ischaemic 
preconditioning. When ischaemic preconditioning was carried out in the presence of 
propranolol, the protective effect was lost. Tissues thus treated recovered to 26.4 ± 5.1 % 
which was not significantly different from control, but was significantly (p<0.01) smaller 
than after ischaemic preconditioning without propranolol. Propranolol alone had no 
significant effect on the recovery of tissues (Fig. 6a). 
A similar picture was observed in ventricular tissues. Untreated tissues recovered to 22.4 
± 2.8 % of pre-ischaemic values in the first fifteen minutes of reoxygenation. Ischaemic 
preconditioning significantly (p<0.05) increased this value to 39.0 ± 5.2 %. Propranolol 
had no significant effect on recovery when given alone, however when combined with 
ischaemic preconditioning, recovery at this time point was significantly (p<0.01) less 
than ischaemic preconditioning alone, and not significantly different from control (Fig.
6b).
By 60 minutes after reoxygenation, however, the beneficial effect of ischaemic 
preconditioning upon recovery was lost (Fig. 7).
Effect of β-adrenoceptor-mediated preconditioning on contractile 
recovery































































Recovery of developed tension in tissues which had received a preconditioning exposure 
of isoprenaline was not different from control in either tissue at 15 minutes after 
reoxygenation (Fig. 6). However, after 60 minutes reoxygenation in atria, the isoprenaline 
treated tissues had recovered to 75.8 ± 16.6% (Fig. 7a), significantly (p<0.05) greater 
than controls which recovered to 47.9 ± 2.3%. This increase was blocked in propranolol 
treated tissues to 44.0 ± 3.0 % which was significantly (p<0.05) smaller than isoprenaline 
preconditioned tissues, and not significantly different from controls. Propranolol alone 
had no significant effect on recovery at this time point (Fig. 7a). Isoprenaline treatment 
did not improve recovery of function in ventricular tissue at either 15 or 60 minutes (Figs. 
6b and 7b).
Discussion
We have demonstrated cardioprotection by ischaemic preconditioning in both atria and 
ventricles. This was manifest by improved functional recovery at 15 minutes after 
reoxygenation in preconditioned tissues compared with control. Pretreatment of atrial 
tissues with the non-selective β-adrenoceptor agonist isoprenaline, also resulted in 
improved functional recovery, although this was manifest later, 60 minutes after 
reoxygenation. The failure of β-adrenoceptor-mediated preconditioning to protect 
ventricular tissue in this model is unlikely to reflect the fact that ventricular tissue cannot 
be preconditioned by β-adrenoceptor activation, because isolated whole-heart models 
have demonstrated that post ischaemic cardiac function can be improved by β-
adrenoceptor preconditioning (Frances et al. 2003), a fact which would necessitate a 
protective effect on the left ventricle. Thus, the failure to demonstrate protection in this 
study either reveals a peculiarity of this model or of the right ventricle.
It has been suggested that ischaemia-induced release of catecholamines in the heart is a 
mechanism by which ischaemic preconditioning induces a protective state (Broadley and































































Penson 2004). Catecholamine release and subsequent activation of β-adrenoceptors has 
also been implicated in the mechanism of cardioprotection achieved by administration of 
opioids (β2) (Huang et al. 2007) and anaesthetics (β1) (Lange et al. 2006b). However, 
controversy remains as to whether activation of β-adrenoceptors is an essential part of 
ischaemic preconditioning, or whether there are redundancies in the pathway which leads 
to protection. – that is to say, that preconditioning could be activated by β-adrenoceptors, 
but equally well by unrelated receptors. In the isolated rat heart, depletion of endogenous 
catecholamines by reserpine does not affect the improved functional recovery or 
reduction in markers of cell death (creatine kinase and lactate dehydrogenase) in hearts 
that had undergone ischaemic preconditioning (Frances et al. 2003; Weselcouch et al.
1995). In rabbits in vivo, it has been demonstrated that blockade of β1-adrenoceptors by 
esmolol had no effect on the infarct-size limitation afforded by ischaemic preconditioning
(Iliodromitis et al. 2004). However, a study in Langendorff perfused rabbit hearts showed 
protection of ischaemic preconditioning against necrosis was blocked by the β1-
adrenoceptor antagonist CGP-20712A (Spear et al. 2007). In a mouse Langendorff 
model, preconditioning protection (improved functional recovery and reduced infarct 
size) was abolished in knockout animals lacking the β2-adrenoceptor (Tong et al. 2005).  
It would seem likely that the reliance of ischaemic preconditioning on β-adrenoceptor 
activation varies between species and indeed different models, and the varying conditions 
and endpoints used in studies account for the apparently contradictory results observed. 
A number of other endogenous mediators have been demonstrated to mimic 
preconditioning, including adenosine (Carr et al. 1997), nitric oxide (Cohen et al. 2006), 
opioids (Schultz et al. 1995, 1996) and anaesthetics (Cason et al. 1997). Thus,
preconditioning may be triggered by a number of independent mechanisms. This is an 
important question in the clinic, where β-adrenoceptor antagonists are administered for 
the treatment of angina, hypertension and heart failure (Mehta 2006). Ischaemic 
preconditioning can be used as a protective strategy prior to cardiac surgery. It is thought 
that angina attacks may also induce preconditioning that can be protective against the 
damage sustained during a later myocardial infarction (Kloner and Rezkalla 2006). 































































Therefore it is important to understand how these protective phenomena may be modified 
by commonly used β-blocking medication.
It is possible that positive inotropes such as isoprenaline could result in preconditioning 
by causing the energy demands of the tissue to exceed the capacity of diffusion to supply 
the substrates, and remove the waste products of metabolism. Indeed, it has been noted 
that rapid pacing of the heart can mimic preconditioning by inducing ischaemia (Vegh et 
al. 1991). Such an effect might be exaggerated in a model such as we used, in which there 
is no flow of buffer through blood vessels in the tissue, and the core of the preparation is 
entirely dependent on diffusion to receive oxygen and nutrients. However, there is a large 
body of evidence, from in vivo and Langendorff isolated heart experiments, in which the 
myocardium is inevitably better supplied with perfusate via the coronary vasculature and 
are therefore less dependent on diffusion, that activation of protein kinases cascades as a 
result of β-adrenoceptor activation results in the heart undergoing adaptive changes and 
becoming resistant to later ischaemic damage. Protein kinase A (PKA) has often been 
implicated in the preconditioning achieved by β-adrenoceptor agonists (Lochner et al. 
1999; Robinet et al. 2005). This is to be expected, as cAMP is also an essential mediator 
in classic β-adrenoceptor signalling leading to positive inotropic and chronotropic effects 
of β-adrenoceptor agonists (May et al. 1985).  
In this study, the beneficial effects of ischaemic preconditioning on post-ischaemic 
recovery were blocked by the non-selective β-adrenoceptor antagonist, propranolol, 
suggesting an important role for β-adrenoceptors in ischaemic preconditioning in this 
model. However, the timecourses of β-adrenoceptor-mediated and ischaemic 
preconditioning were different; ischaemic preconditioning led to improved contractile 
function early after reoxygenation (15 minutes) but not after 60 minutes. At this later time 
point, however, β-adrenoceptor agonist pretreatment led to improved function. 
Furthermore, tissues preconditioned by ischaemia and by β-adrenoceptor stimulation 































































behaved differently from one another during ischaemia. Ischaemic preconditioning led to 
a reduction in the magnitude of ischaemic contracture which is consistent with a 
protective effect. Ischaemic contracture is of the rigor type, and develops under 
conditions where ATP concentrations are insufficiently high to break actin-myosin cross-
links (Piper et al. 2003). Rigor contracture can lead to cytoskeletal damage and thus any 
reduction in the magnitude of contracture is likely to be protective. In contrast, β-
adrenoceptor stimulation by isoprenaline did not reduce the magnitude of contracture in 
either atria or ventricles even in tissues where there was improved recovery at 60 
minutes. Thus, ischaemic preconditioning may involve wider ranging beneficial effects 
than those seen with β-adrenoceptor-mediated preconditioning.
In agreement with studies in whole hearts (Kolocassides et al. 1995), ischaemic 
preconditioning in ventricular preparations reduced the time taken to achieve maximum 
contracture. It is difficult to make predictions on the recovery of ischaemic tissues based 
on the profile of ischaemic contracture (Pantos et al. 2006). However, the difference seen 
in these experiments between ischaemic- and β-adrenoceptor-mediated preconditioning 
suggest that different mechanisms may be involved in each. 
This study is limited by the fact that it was not possible to measure infarct size in this 
model. Thus, we were unable to distinguish between functional impairment as a result of 
cell death and reversible contractile dysfunction (stunning). Additionally, the model uses 
atrial appendage tissue and right ventricular strips rather than left ventricle which is of 
more functional importance. However, these tissues were chosen because of their thin 
walls, in order to minimise diffusional limitations into the tissue. We believe that these 
preparations provide a convenient model for studying the functional implications of 
interventions before, during and after simulated ischaemia. Additionally, our use of a 
non-selective β-adrenoceptor agonist and antagonist do not enable us to identify which 































































receptor subtype is involved in the protection seen, which future studies will examine in 
more detail.
In conclusion, we have demonstrated that isolated left atria and right ventricles can be 
used as a convenient model of ischaemic and pharmacological preconditioning. 
Ischaemic- and β-adrenoceptor-mediated preconditioning both led to an improvement in 
post ischaemic contractile function. The protective effects in both cases were abrogated 
by propranolol. However, the timecourse of protection during ischaemia and 
reoxygenation was different in each case suggesting that ischaemic preconditioning 
involved more complex mechanisms than the simple release of catecholamines and 
subsequent signalling activation of β-adrenoceptors. We believe that simulated ischaemia 
in isolated cardiac tissues, as used in this model, represents an important and valid 
technique for exploring the effects of interventions upon ischaemic contracture and post-
ischaemic contractile dysfunction. In terms of physiological relevance, this model falls 
between isolated whole hearts and cell culture, but is not subject to the problems of cell 
differentiation seen in culture and is not complicated by the effects upon coronary flow 
which would be expected when β-adrenoceptor agonists are administered in a 
Langendorff heart preparation. Indeed, the effects seen in this model must occur at the 
level of the myocardium. The most clinically relevant finding of this study was that the 
functional improvements of ischaemic preconditioning were blocked by propranolol. This 
finding mirrors the result of other studies (Spear et al. 2007; Tong et al. 2005) in which β-
adrenoceptor activation has been shown necessary for the protection by ischaemic 
preconditioning. However, in our study, the protective effect must be at the level of the 
myocardium. This requires further investigation in vivo and in vitro of the β-adrenoceptor 
subtypes that are involved because many patients with cardiovascular diseases take β-
adrenoceptor antagonists which may have the potential to abrogate the effects of  
ischaemic preconditioning induced prior to cardiac surgery (Laskey 2005) or as a result 
of angina attacks (Kloner and Rezkalla 2006) .
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Fig. 1 Experimental Protocols. Time (minutes) is shown along the abscissa with the 
point of reoxygenation designated 0. White regions correspond to normoxic 
conditions, black simulated simulated ischaemia and grey, drug treatment.
Control  n=11
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Fig. 2 A representative trace from a ventricular preparation exposed to simulated 
ischaemia and reoxygenation. S represents the final minutes of the stabilisation 
period. Time (minutes) from reoxygenation are shown along the abscissa. Note the 
rapid fall in developed tension during simulated ischaemia and the increased diastolic 
tension indicating ischaemic contracture. Diastolic and developed tension both 
recover rapidly over the first 15 minutes of reoxygenation and more slowly thereafter.






























































































































Fig. 3 Mean (+SEM) magnitude of ischaemic contracture (maximum increase in 
diastolic tension (g) during simulated ischaemia) in a) atria and b) ventricular strips. * 
indicates p<0.05; *** indicates p<0.001 






























































































































Fig. 4 Mean (+SEM) time (minutes) into simulated ischaemia at which maximum 
contracture was reached in a) atria and b) ventricular strips. ** indicates p<0.01; *** 
indicates p<0.001. 































































Fig. 5 Timecourse of developed tension throughout ischaemia and reperfusion in 
control and ischaemic pre-condition d (IPC) tissues in a) atria and b) ventricles. Mean 
developed tension (+SEM) is expressed as a percentage of the developed tension 
achieved at the end of the stabilisation period. 






























































































































Fig. 6 Mean developed tension (+SEM) after 15 minutes reoxygenation in a) atria and 
b) ventricular strips. Developed tension is expressed as a percentage of the developed 
tension achieved at the end of the stabilisation period. * indicates p<0.05; ** indicates 
p<0.01 .






























































































































Fig. 7 Mean developed tension (+SEM) after 60 minutes reoxygenation in a) atria and 































































b) ventricular strips. Developed tension is expressed as a percentage of the developed 
tension achieved at the end of the stabilisation period. * indicates p<0.05.
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